ProfileGDS5678 / 1451461_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 8% 6% 6% 7% 17% 7% 63% 55% 70% 8% 6% 20% 7% 5% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.22078
GSM967853U87-EV human glioblastoma xenograft - Control 22.128156
GSM967854U87-EV human glioblastoma xenograft - Control 32.136016
GSM967855U87-EV human glioblastoma xenograft - Control 42.1027
GSM967856U87-EV human glioblastoma xenograft - Control 52.3618717
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.205067
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8199563
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3720655
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.3983570
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.192288
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.085596
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4526920
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.150427
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.086195